The Accuracy of Heart Rate Monitoring by Some Wrist-Worn Activity Trackers

Background: Activity trackers may motivate persons to engage in healthy behaviors. They are also used in research and may help manage chronic conditions related to lifestyle (1). New devices have emerged as alternatives to traditional heart rate trackers, which require a separate chest strap. One type is a wrist-worn tracker with a light-emitting diode (LED). It measures the heart rate from tiny changes in skin blood volume by using light reflected from the skin. These new devices are unobtrusive and appropriate for continuous, long-term wear. Although previous studies have shown that they are generally accurate for measuring the number of steps a person takes, less is known about their accuracy when measuring heart rate (24). Objective: To determine the accuracy of the heart rate measured by LED-dependent, wrist-worn activity trackers. Methods: We studied 4 commercial, wrist-worn activity trackers that use LEDs to measure heart rate. Study participants were 40 healthy consenting adults aged 30 to 65 years without cardiovascular conditions. For each participant, we placed 2 trackers on each wrist in random order by right versus left and by proximal versus distal location on the wrist. We then performed electrocardiography on the seated participant and measured the resting heart rate at 1-minute intervals for 10 minutes for each of the 4 trackers. Next, we measured the heart rate at 1-minute intervals for 10 minutes while the participant exercised on a treadmill at 65% of the maximum heart rate, which we calculated as 220 beats/min minus the participant's age in years. We used BlandAltman plots to compare the heart rates measured by electrocardiography with those measured by each of the wrist-worn trackers. We used the MethComp package in R (R Foundation for Statistical Computing) to create a mixed-effects model for linked replicate measurements to summarize these and other comparisons (5). Findings: Participants had a mean age of 49.3 years (SD, 9.5) and a mean body mass index of 25.1 kg/m2 (SD, 3.9), and 50% were women. The Figure plots individual comparisons among the heart rates measured by electrocardiography and the trackers, and we summarized the amount of agreement with a statistic known as the limits of agreement (a narrower range is better) (Appendix Table). For participants at rest, the agreement was best for the Fitbit Surge (Fitbit), which had the narrowest limits of agreement (5.1 to 4.5 beats/min), worst for the Basis Peak (Basis) (17.1 to 22.6 beats/min), and intermediate for the Fitbit Charge (Fitbit) (10.5 to 9.2 beats/min) and Mio Fuse (Mio Global) (7.8 to 9.9 beats/min). When participants exercised at 65% of the maximum heart rate, the limits of agreement were relatively poor for all the activity trackers (Mio Fuse, 22.5 to 26.0 beats/min; Basis Peak, 27.1 to 29.2 beats/min; Fitbit Surge, 34.8 to 39.0 beats/min; and Fitbit Charge, 41.0 to 36.0 beats/min). The repeatability coefficient determined how close 1 measurement was to another when using the same device in the same study participant under the same conditions (smaller values are better) (Appendix Table). For example, the repeatability coefficient for electrocardiogram was 5.3 beats/min at rest and 9.1 beats/min during exercise. In comparison, the repeatability coefficient at rest was 4.2 beats/min for the Fitbit Surge, 9.3 beats/min for the Fitbit Charge, 10.9 beats/min for the Mio Fuse, and 19.3 beats/min for the Basis Peak. During exercise, the repeatability coefficient was 20.2 beats/min for the Basis Peak, 20.6 beats/min for the Fitbit Surge, 21.6 beats/min for the Fitbit Charge, and 23.7 beats/min for the Mio Fuse. Tracker location on the arm did not affect any of these measurements. Figure. Comparison of heart rates measured by electrocardiography and each tracker, at rest and with moderately intense activity. Each point represents the heart rate measured at the same time by electrocardiography and a tracker. The x-axis describes the mean of the 2 values in beats per minute, and the y-axis describes the difference between the 2 values in beats per minute. Points identified by a unique combination of color and symbol are measurements in a single study participant. On the y-axis, points above 0 indicate that the tracker value was higher than that of electrocardiography and those below 0 indicate that the tracker value was lower. The black horizontal lines indicate the mean difference between the heart rate measured by the tracker and electrocardiography, which is known as the bias. (On this small scale, many of the black lines are so close to the value of 0 on the y-axis that appreciating the direction and size of the bias is difficult. See the Appendix Table for bias values.) The red horizontal lines indicate the limits of agreement and include approximately 95% of the differences. Appendix Table. Summary Measures Comparing Heart Rates Measured by Electrocardiograph Versus Each Tracker and Within Each Tracker* Discussion: Some of the wrist-worn activity trackers that we studied measured values for heart rate that were similar to those measured by electrocardiography, and some measured similar values when the same device was used to repeat the measurements in the same study participant under the same conditions. However, all of the trackers performed better at rest than during moderately active exercise, performance at rest was better for some trackers than for others, and limited repeatability for each tracker caused more problems than poor agreement between each tracker and electrocardiography. Thus, although wrist-worn trackers may help monitor daily activity, more research is needed before we can confidently conclude that the monitoring feature for heart rate is sufficient to help clinicians advise their patients about health issues and conduct clinical trials that require a high level of accuracy and reliability for heart rate measurement.

[1]  Daniel T Anderson,et al.  Oxycontin: the concept of a "ghost pill" and the postmortem tissue distribution of oxycodone in 36 cases. , 2002, Journal of analytical toxicology.

[2]  Dimitris Mavridis,et al.  Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials. , 2016, European heart journal.

[3]  S. Thompson,et al.  How should meta‐regression analyses be undertaken and interpreted? , 2002, Statistics in medicine.

[4]  B. Carstensen,et al.  Statistical Models for Assessing Agreement in Method Comparison Studies with Replicate Measurements , 2008, The international journal of biostatistics.

[5]  U. Wisløff,et al.  Accuracy of Heart Rate Watches: Implications for Weight Management , 2016, PloS one.

[6]  R. Furberg,et al.  Systematic review of the validity and reliability of consumer-wearable activity trackers , 2015, International Journal of Behavioral Nutrition and Physical Activity.

[7]  R. Nelson,et al.  Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction. , 2016, JACC. Heart failure.

[8]  Richard D Riley,et al.  Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data: The PRISMA-IPD Statement , 2015 .

[9]  Simon G Thompson,et al.  Can meta-analysis help target interventions at individuals most likely to benefit? , 2005, The Lancet.

[10]  R. Dell,et al.  Quantitative displacement of acid-base equilibrium in metabolic acidosis. , 1967, Annals of internal medicine.

[11]  David R Bassett,et al.  Device-based monitoring in physical activity and public health research , 2012, Physiological measurement.

[12]  M. Fulop A guide for predicting arterial CO2 tension in metabolic acidosis. , 1997, American journal of nephrology.

[13]  S. Bains,et al.  Ghost pill: knowledge and awareness of this phenomenon among health care professionals , 2014 .

[14]  Wing W. Chan,et al.  Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. , 2016, JAMA cardiology.

[15]  J. Soar,et al.  What follows refractory cardiac arrest: Death, extra-corporeal cardiopulmonary resuscitation (E-CPR), or uncontrolled donation after circulatory death? , 2016, Resuscitation.

[16]  H. Wen,et al.  Ghost-Pill-Buster: A Case Study of Intact Levetiracetam Extended-Release Tablets after Dissolution Testing , 2016, CNS Drugs.

[17]  Dermot Phelan,et al.  Accuracy of Wrist-Worn Heart Rate Monitors , 2017, JAMA cardiology.

[18]  Frédéric Adnet,et al.  Kidney retrieval after sudden out of hospital refractory cardiac arrest: a cohort of uncontrolled non heart beating donors , 2009, Critical care.

[19]  L. Morrison,et al.  Validation of a rule for termination of resuscitation in out-of-hospital cardiac arrest. , 2006, The New England journal of medicine.

[20]  P C Lambert,et al.  A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. , 2002, Journal of clinical epidemiology.

[21]  M. Durão,et al.  Kidney transplantation from donors without a heartbeat. , 2002, The New England journal of medicine.

[22]  Tongeji E. Tungaraza,et al.  Curse of the ghost pills: the role of oral controlled-release formulations in the passage of empty intact shells in faeces. Two case reports and a literature review relevant to psychiatry , 2013, Therapeutic advances in drug safety.